We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Jennifer Lalama
Jennifer Lalama
Products
PRODUCTS
Chemco Corp.
Damaris Y. Hernandez
and
Jennifer Lalama
Price:
$117.00
View
Dharma Research, Inc.
Dorothy P. Kramer
,
Jennifer Lalama
, and
Jamirya S. Weatherly
Price:
$117.00
View
Infusion Systems of SW Florida, Inc. dba Myerlee Pharmacy
Steven A. Brettler
and
Jennifer Lalama
Price:
$117.00
View
USpharma Ltd.
Jennifer Lalama
Price:
$117.00
View
Ionetix Corp.
Jennifer Lalama
and
Kayla V. Sprague
Price:
$117.00
View
All Pharma, LLC
Jennifer Lalama
Price:
$117.00
View
Noven Pharmaceuticals, Inc.
Lillian M. Colon-Mcknight
,
Jennifer Lalama
, and
Kayla V. Sprague
Price:
$117.00
View
PLD Acquisitions, LLC dba Avema Pharma Solutions
Jennifer Lalama
and
Teresa I. Navas
Price:
$117.00
View
CoreRx, Inc.
Vivin George
,
Jennifer Lalama
,
Kayla V. Sprague
, and
Yifan Wang
Price:
$117.00
View
Strides Pharma, Inc.
Jennifer Lalama
and
Steven J. Rush
Price:
$117.00
View
View All Products by Jennifer Lalama
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
